



Innovative financing to save more lives, faster

The International Finance Facility for Immunisation VACCINE BONDS

Treasury manager:





The International Finance Facility for Immunisation VACCINE BONDS

CONTENTS

Financing immunisation

IFFIm financial strength

IFFIm saves lives

IFFIm meets social bond principles

Contact

1. Financing immunisation



A child not immunised today may be a life lost tomorrow. Let's invest in life now.

Cyrus Ardalan, IFFIm Board Chair

BASIC HEALTH CENTRE



Overview of financing immunisation

Since 2006, **IFFIm** raises money for **Gavi**, by issuing **Vaccine Bonds** in the capital markets and repaying these bonds with long-term donor pledges



For Gavi

- accelerates the rate of immunisation in poor countries: saving more lives, faster
- reduces vaccine prices and secures supply by increasing long-term funding predictability



For investors

- portfolio diversification and attractive risk-adjusted returns
- an award-winning socially responsible investment



• significant immediate impact to

- significant immediate impact to immunising children & saving lives
- IFFIm has in aggregate been able to raise financing at a lower funding cost than the weighted composite cost of donors



The world's immunisation challenge

140 million children are born worldwide each year



but almost 20 million are not fully vaccinated



Because of inequity, many children never have access to life-saving vaccines.



As many children as born each year in Germany, Italy & Spain combined **1.5 million** will then die from diseases that vaccines prevent



Gavi addresses the challenge

Gavi is a public-private global health partnership

The Alliance was created in 2000 to address stagnating and declining immunisation rates in the poorest countries





Contact

IFFIm: a tool for Gavi to save more lives

Long-term, predictable funding from IFFIm strengthens Gavi's ability to invest large amounts as needed, encouraging more vaccine production while reducing prices.

Puts long-term funding from donor countries to work **immediately**

Frontloading resources over a shorter term, or drawing down funds over a longer period, **gives Gavi flexibility** to use funds when they are needed most.





IFFIm's funding mechanism





The IFFIm partnership

C-II

FERENS

1. DONORS

Long-term pledges from 10 sovereign governments enable IFFIm to raise money in the capital markets

2. IFFIm BOARD OF DIRECTORS

IFFIm's Board reviews disbursement of funds and is responsible for funding decisions

4. GAVI

As the sole beneficiary of IFFIm funds, Gavi accelerates access to immunisation for children in poor countries



GOVERN

IFFIm

3. THE WORLD BANK

As IFFIm's treasury manager, the World Bank manages IFFIm's finances to the same prudent standards as it does its own finances



IFFIm donors

IFFIm Vaccine Bonds are backed by long-term, irrevocable and legally binding pledges from ten sovereign governments:

Country	Amount comm i (US\$m equiv.	Grant Period
United Kingdom (AA/Aa2/AA-)	2,980	23 years
France (AA/Aa2/AA)	1,884	20 years
Italy (BBB/Baa3/BBB)	635	20 years
Norway (AAA/Aaa/AAA)	532	25 years
Australia (AAA/Aaa/AAA)	284	20 years
Spain (A/Baa1/A-)	240	20 years
The Netherlands (AAA/Aaa/AAA)	181	10 years
Sweden (AAA/Aaa/AAA)	38	15 years
South Africa (BB-/Ba1/BB)	20	20 years
Brazil (BB-/Ba2/BB-)	20	20 years
	Total 6,814	



IFFIm's Board of Directors

IFFIm's Board is comprised of six directors with extensive backgrounds in banking, capital markets and development finance



Cyrus Ardalan (Chair)

Cyrus is Non-Executive Chairman of Citigroup Global Markets and Chairman of OakNorth Bank. Previously he was a Vice Chairman of Barclays, serving in several key roles in government relations, emerging markets and investment banking.



Fatimatou Zahra Diop

Fatimatou retired as Secretary General of the Central Bank of West African States (BCEAO) then co-founded Afrivac which works with public & private sector partners to promote strengthening African countries' budgets.



Bertrand de Mazières (Audit Committee Chair)

Bertrand is Director General for Finance at the European Investment Bank. He has been in French public administration, financial market regulatory authorities and International Financial Institutions.



Jessica Pulay Jessica is Co-Head of Policy and Markets at the UK

Debt Management Office (DMO). She spent 16 years at the European Bank for Reconstruction and Development and is a trustee of the Wallace Collection.



Doris Herrera-Pol

Doris is recently retired from the World Bank where she was the global head of capital markets. Before joining the World Bank, Doris conducted sovereign debt negotiations for the Dominican Republic.



Helge Weiner-Trapness

Helge is Founding Partner of Quintus Partners providing investment advisory and capital raising services. He spent 14 years in Hong Kong where he was most recently Managing Director and Co-Global Head of the Financial Institutions Group at Barclays.




The World Bank is IFFIm's treasury manager

The World Bank's triple A rating, 70 years of experience in capital markets and prudent financial management help ensure IFFIm's long-term stability. The World Bank manages IFFIm's financial operations.





IFFIm – a single purpose issuer of social bonds





IFFIm Vaccine Bond offers to date

Annual funding volume depends on needs for immunisation programmes in partner countries and refinancing needs for maturing debt

IFFIm sells bonds to retail and institutional investors and issues a variety of transactions ranging from larger, more liquid issues to smaller, more targeted bonds

Average maturity is 3-5 years

Most recent transaction

2017: \$300mil / 3 yr / Benchmark Apr 2019: \$50mil / 3 yr / Sukuk 2019: NOK600m / 6 yr / Zero coupon

Year	Bond	US\$m equiv.
2006	Inaugural USD Benchmark (USD)	1,000
2008	Uridashi (ZAR)	223
2009	Uridashi (AUD/ZAR/NZD) Dual Tranche Retail & Institutional (GBP) Uridashi (USD/AUD) & (ZAR/AUD)	1,102
2010	Uridashi (ZAR) & (AUD/BRL/ZAR) & (AUD) AUD Kangaroo Bond Benchmark (AUD) Eurobond (AUD)	851
2011	Uridashi (BRL) & (AUD/BRL/ZAR)	394
2012	Uridashi (AUD/ZAR) & (AUD)	137
2013	Uridashi (TRY/ZAR) Floating Rate USD Benchmark (USD)	839
2014	Inaugural sukuk (USD)	500
2015	Sukuk (USD)	200
2016	Floating Rate USD Benchmark (USD)	500
2017	Floating Rate USD Benchmark (USD)	300
2019	Sukuk (USD) private placement Zero Coupon Note (NOK)	116
		Total 6.162





CONTROL OF CONTROL OF

What makes IFFIm unique is the combination of financial strength with moral purpose – enabled by financial innovation

Gordon Brown, Former Prime Minister of the UK

IFFIm's balance sheet

ssets		Liabilities	
December 2019	US\$m	December 2019	US\$m
Sovereign pledges	2,074	Bonds payable	510
Funds held in trust	428	Grants payable	357
Other assets		Other liabilities	521
Total Assets	2,502	Total Liabilities	1,388



ontact

Unique features ensure high credit strength

Highly rated grantor countries	Innovative & effective financing instrument
 The UK is the largest donor, pledging around 46% of remaining donor payments France, Norway, Italy, and Australia accounting for 29%, 9%, 6%, 5% respectively 	 Vaccine bonds provide a portfolio diversification opportunity with attractive risk-adjusted returns in an award-winning socially responsible investment
Treasury management by the World Bank	Legally binding pledges
 Treasury assets are conservatively invested Foreign exchange risk is mitigated through hedging activities 	 Irrevocable and legally binding pledges to provide grants to Gavi, the Vaccine Alliance
Conservative financial policies	Strong donor commitment
 Liquidity buffer under which IFFIm must maintain a portfolio of liquid assets that cover debt service over the next 12 months Maximum leverage limit at 70.3% as of 4Q 2019 Gearing ratio at 31 December 2019 was 10% 	 Donors committed to disburse grants over more than 20 years up to 2037 Nominal value of pledges totaled US\$ 6.8b as of May 2020



Credit rating linked to donor ratings

IFFIm ratings by:

Fitch Ratings	AA- (negative outlook)
Moody's	Aa1 (stable)
S&P	AA (negative outlook)

Close link of IFFIm's ratings to ratings of largest donors:

Moody's (July 2019): "The credit profile of IFFIm reflects very high liquidity, the strong commitment from donor governments and the involvement of the World Bank as treasury manager."

Fitch Ratings (March 2020): "IFFIm's ratings rely primarily on support from donors as their grant payments ultimately back IFFIm's repayment of its bond issuances."

S&P (March 2019): "We affirmed our ratings on IFFIm based on our view of the commitment of its highly rated contributors to its mandate of supporting child immunization programs in the world's poorest countries."



STANDARD & POOR'S RATINGS SERVICES

RatingsDirect^{*}

International Finance Facility for Immunisation

Primary Crodit Asalyst: Elle Hivitol Diereka, London (40, 207-176-7902; elle heriard dathevall@tranduetlandpoors.com Secondary Contact: John B Chambers, C7A, New York (1) 212-438-7344, john.chambers@tranduetlandpoors.com Research Contributor: Marina Sindon, Landor: marina artismi@tranduetlandpoors.com Analytical Groups Contact: Sovernigsflaurope: Soversigsflaurope@tranduetlandpoors.com Table Of Contents

Major Rating Factors

Rationale

Outlook

Organization And Related Entities

Grant Payment Condition

IFFIm Gearing Ratio Limit

Financial Statements

Related Criteria And Research

MARCH 28, 2014 1



3. IFFIm saves lives

Vaccines protect against most major child killers:

including: pneumococcal disease, rotavirus, measles, tetanus, diphtheria and polio

Vaccines provide health, social and economic gains:

reducing death and disease, healthcare cost savings and productivity gains through improved ability to learn and work

Vaccines are a highly costeffective intervention:

cost estimate of eradicating smallpox through immunisation: US\$ 100 million, but now saves the world US\$ 1.35 billion/year



Vaccines are the simplest, most effective, most inexpensive way to save children's lives

Bill Gates, a Gavi founding donor



IFFIm investments help save lives



IFFIm has helped Gavi by increasing its funding for immunisation programmes, resulting in...



>13 million lives saved

~760 million children immunised



Help to reduce vaccine price & secure supply

The **pentavalent vaccine** is effective in eradicating five diseases* that kill ~1 million people every year, but is expensive and was often not available where it's needed most



IFFIm provided:

Help to establish pentavalent programme by frontloading >90% of initial vaccines, encouraging manufacturers to step up vaccine production and reduce its price

Total IFFIm support now exceeds US\$ 1.3b



Gavi now able to procure pentavalent vaccines for as low as \$0.68 a dose, a price reduction of over 75% since 2006

All 73 Gavi countries have introduced pentavalent vaccine

* diphtheria, pertussis (whooping cough), tetanus, hepatitis B and Haemophilus influenzae type B (Hib)



Help to prevent disease outbreaks

Outbreaks of yellow fever and measles in Africa in past years called for fast action Time. was short to vaccinate people before the disease spread.



IFFIm provided:

Yellow fever: US\$ 90.9 million for emergency stockpiles of vaccines to stave off epidemics & run preventive campaigns Measles: US\$ 139 million for targeted

mass campaigns against the diseases



Helping Gavi to protect:

Over 189 million people against yellow fever disease through campaigns and routine delivery


An additional **328 million children** against measles through campaigns



Immunisation creates new outcomes

Vaccination sets off a positive cycle in a child's life.

We do not usually think of vaccination as an investment, but research published in 2019 suggests that vaccination has a good return on investment with every US\$ 1 spent on immunisation \$54 are saved in health care costs, lost wages and lost productivity











Socially Responsible Investment (SRI) Innovation of the Decade

mtn-i, the news / analytics provider

Vaccine bonds helped pioneer SRIs

IFFIm offers investors a **unique opportunity** to combine an attractive financial investment with an exceptional social purpose - generating a positive impact on society

Advantages for Investors:

- Alignment with social bond principles
- Measurable impact
- Attractive risk-adjusted returns
- Portfolio diversification





Compliant with ICMA Social Bond Principles

SBP components	Requirements met by IFFIm
Use of proceeds	 Proceeds go to support Gavi's mission to accelerate the availability of life-saving vaccines for the world's most vulnerable children
Project evaluation & selection	 Gavi's potential vaccine investments are evaluated by an Independent Review Committee (IRC), which is made up of independent technical experts, and which reports to the Gavi Board Gavi is responsible for the selection of immunisation and/or health systems strengthening programmes for which IFFIm provides funding
Management of proceeds	 IFFIm is currently forecasted to disburse US\$1.7 billion to Gavi between 2020-2025 Gavi manages the allocation, disbursement and tracking of IFFIm's proceeds in a transparent manner as per its program funding policies
Monitoring & reporting	 IFFIm provides quarterly reports how it allocates funds to programmes, and publishes audited financial statements annually Gavi evaluates ongoing programmes as per its evaluation policy, and monitors and reports on its impact annually, using criteria set by its Board



For more information, see: <u>www.iffim.org/funding-gavi</u> <u>www.gavi.org/support/process/apply/independent-review-committee</u>

IFFIm & the UN Sustainable Development Goals

3 GOOD HEALTH AND WELL-BEING IFFIm supports Gavi's mission to save children's lives and protect people's health by increasing equitable use of vaccines in lower-income countries is directly aligned with the UN Sustainable Development Goal 3; which aims to end preventable deaths of newborns and children under 5 years of age by 2030.



The global partnership between the donors, the Board of Directors, the World Bank, Gavi and Socially Responsible Investors working for Gavi's mission is aligned with the UN Sustainable Development Goal 17 which recognises the need for stronger commitment to partnership and cooperation to achieve sustainable development.



IFFIm widely recognised for innovation

EUROWEEK THE NEWSPAPER OF THE GLOBAL CAPITAL MARKETS IFFIm's inaugural Uridashi bond included among the market's **25 most influential transactions** by EuroWeek



Cited as **"SRI Innovation of the Decade**" by mtn-i, the news / analytics provider



IFFIm's debut Sukuk was awarded **Social Impact Deal of 2014** by Islamic Finance News





Recognised for its role in investing in and aiding development by the **Action Agenda of the Financing Development Conference** in Addis Ababa, Ethiopia, in 2015. The Action Agenda, endorsed by representatives of the world's governments, stated:

"...We encourage consideration of how existing mechanisms, such as the International Finance Facility for Immunisation, might be replicated to address broader development needs..."



5. Contact IFFIm





International Finance Facility for Immunisation Company 2 Lambs Passage London EC1Y 8BB www.iffim.org

Company limited by guarantee. Registered in England and Wales with number 5857343. Registered as a charity with number 1115413.

Disclaimer

This presentation has been prepared by the International Bank for Reconstruction and Development ("IBRD"), as Treasury Manager for International Finance Facility for Immunisation Company ("IFFIm") for information purposes only, and neither IBRD nor IFFIm makes any representation, warranty or assurance of any kind, express or implied, as to the accuracy, completeness or reliability of any of the information contained herein. The information contained in this material may be subject to change without notice. Neither IBRD nor IFFIm accept any obligation to update any recipient of this presentation as to any such changes. Past performance is not indicative of future results. None of IFFIm, IBRD, or any of its affiliates, advisers (including the lead managers) or representatives shall have any liability whatsoever (in negligence or otherwise) for any loss howsoever arising from any use of this material or otherwise arising in connection with this material. The IFFIm board of directors has not approved this presentation. This presentation is not an offer for sale, or a solicitation of an offer to buy, any notes or other securities of IFFIm.

This presentation and the information contained herein is not for publication, distribution or release, in whole or in part, in or into, directly or indirectly, the United States or to a U.S. Person (as defined in Rule 902 of Regulation S under the U.S. Securities Act of 1933 (the "Securities Act")). Any Notes which have been or will be issued by IFFIm under its Global Debt Issuance Programme or otherwise have not been and will not be registered under the Securities Act and have been, and will only be, offered or sold (1) in the United States or to, or for the account or the benefit of, U.S. persons in a transaction exempt from, or not subject to, the registration requirements of the Securities Act or (2) to non-U.S. purchasers in offshore transactions pursuant to Regulation S adopted under the Securities Act.

This presentation includes "forward-looking information" within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the U.S. Securities Exchange Act of 1934. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements. Statements that describe IFFIm's objectives, plans or goals are or may be forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause IFFIm's actual results, performance or achievements to differ materially from the anticipated results, performance or achievements expressed or implied by these forward-looking statements. Such forward-looking statements speak only as of the date on which they are made.

This presentation is for distribution only to persons who are not a "retail client" within the meaning of section 761G of the Corporations Act 2001 of Australia and are also sophisticated investors, professional investors or other investors in respect of whom disclosure is not required under Part 6D.2 of the Corporations Act 2001 of Australia and, in all cases, in such circumstances as may be permitted by applicable law in any jurisdiction in which an investor may be located. Each person accessing this presentation confirms that they are a person who is entitled to do so under all applicable laws, regulations and directives in all applicable jurisdictions. Neither IFFIm nor any of their directors, employees, agents or advisers accepts any liability whatsoever for any loss (including, without limitation, any liability arising from any fault or negligence on the part of IFFIm or its respective directors, employees, agents or advisers) arising from access to this presentation by any person not entitled to do so.

Each recipient of this presentation is deemed to acknowledge that this presentation is a proprietary document of IFFIm and by receipt hereof agrees to treat it as confidential and not reproduce, redistribute or disclose it, or permit reproduction, redistribution or disclosure of it, to third parties without the prior written consent of the IFFIm. All content (including, without limitation, the graphics, icons, and overall appearance of the presentation and its content) are the property of IFFIm. IFFIm does not waive any of its proprietary rights therein including, but not limited to, copyrights, trademarks and other intellectual property rights.

